06:33 EDT Sarepta (SRPT) down 12% to $11.34 after EU decision on approval
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta rallied on ‘too optimistic’ Elevidys view, says H.C. Wainwright
- Sarepta falls 6% to $12.10 after JPMorgan downgrade to Underweight
- Brazil suspends sales of Sarepta’s Elevidys after deaths
- Sarepta downgraded to Underweight from Neutral at JPMorgan
- Sarepta turns up after Endpoints updates on FDA official’s view on study need